ReviewEuropean journal of clinical pharmacology2024

Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.

Sining Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.